Photofrin® photodynamic therapy: 2.0mg/kg or not 2.0mg/kg that is the question
| Autor: | Claudio Sibata, Ron R. Allison |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
medicine.medical_specialty
Chemotherapy Photosensitizing Agents Clinical variables business.industry medicine.medical_treatment Biophysics Urology Dose-Response Relationship Radiation Photodynamic therapy Dermatology Lower risk Tumor ablation Surgery Light dose Photochemotherapy Oncology Neoplasms Humans Medicine Dosimetry Dihematoporphyrin Ether Pharmacology (medical) Photosensitizer business |
| Zdroj: | Photodiagnosis and Photodynamic Therapy. 5:112-119 |
| ISSN: | 1572-1000 |
| DOI: | 10.1016/j.pdpdt.2008.05.004 |
| Popis: | Summary Photodynamic therapy (PDT) is an innovative minimally invasive therapy that has great potential for both tumor ablation and normal tissue preservation. However, while in recent years the standards of surgery, radiation and chemotherapy have dramatically improved in terms of outcomes and morbidity, the same cannot be said of PDT in general and Photofrin ® -based PDT in particular. As currently practiced PDT dosimetry has not really improved tumor ablation and diminished side effects over reports from two decades ago. We critically examine the clinical variables available for PDT dosimetry and conclude that the simple maneuver of diminishing drug dose, with an appropriate increase in light dose, can enhance disease control with a significantly lower risk of morbidity. This conclusion should also be applicable to most systemically introduced photosensitizer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect